How to Get Dayvigo (Lemborexant) in Pennsylvania

What Is Dayvigo and Why Pennsylvania Patients Are Asking About It

Dayvigo is a dual orexin receptor antagonist (DORA) approved by the FDA in December 2019 for the treatment of insomnia disorder in adults [1]. It blocks both OX1R and OX2R orexin receptors, reducing wakefulness drive rather than suppressing the central nervous system broadly. The clinical consequence is meaningful: patients fall asleep faster and stay asleep longer without the next-morning sedation patterns seen with older benzodiazepine receptor agonists.

The SUNRISE-1 trial, a phase 3 randomized controlled study (N=1,006) published in JAMA Network Open, found that lemborexant 5 mg reduced subjective sleep onset latency by 17.0 minutes and lemborexant 10 mg reduced it by 18.5 minutes compared to placebo at month 1 [2]. Objective polysomnographic data from SUNRISE-1 showed that the 10 mg dose reduced wake after sleep onset (WASO) by 40.7 minutes versus placebo (P<0.001) [2]. SUNRISE-2 extended those findings across 12 months, confirming sustained efficacy without tolerance development [3].

Pennsylvania ranks among the top ten states for telehealth utilization since the 2020 pandemic-era prescribing expansions, and interest in non-benzodiazepine sleep agents has grown accordingly. Patients searching for "how to get Dayvigo in Pennsylvania" typically want to know which prescribers can help them, what insurance will cover, and how quickly they can fill the prescription.

Who Can Prescribe Dayvigo in Pennsylvania

Any Pennsylvania-licensed prescriber with DEA Schedule V authority may write a lemborexant prescription. That group includes MDs, DOs, nurse practitioners (CRNPs), and physician assistants (PAs) practicing within their scope. Pennsylvania Act 112 of 2020 and subsequent telehealth regulations allow CRNPs and PAs to prescribe via synchronous audio-video encounters without a prior in-person visit, provided the prescriber completes a clinical evaluation adequate to establish a diagnosis [4].

Because lemborexant is Schedule V, DEA regulations permit prescriptions to be transmitted electronically, phoned in, or faxed. Mail-order fills of up to a 90-day supply are permissible for Schedule V substances under federal law, which makes telehealth plus mail-order a fully legal pathway for Pennsylvania patients [5]. Schedule V drugs do not require the same hard-copy or in-person dispensing constraints that apply to Schedule II through IV substances.

A prescriber performing a telehealth visit for insomnia will typically ask about sleep-onset versus sleep-maintenance symptoms, the duration and frequency of insomnia episodes, prior treatment attempts (over-the-counter melatonin, diphenhydramine, cognitive behavioral therapy for insomnia, zolpidem, or eszopiclone), medical and psychiatric comorbidities, current medications, and alcohol or substance use history. That clinical interview, combined with a validated tool such as the Insomnia Severity Index (ISI), is generally sufficient to support a lemborexant prescription without ancillary labs.

The American Academy of Sleep Medicine (AASM) 2017 clinical practice guideline for chronic insomnia states: "We suggest that clinicians use lemborexant... as a treatment for sleep onset and/or sleep maintenance insomnia in adults" [6]. Pennsylvania prescribers may rely on that guideline language when documenting medical necessity for prior authorization.

Step-by-Step: Getting a Dayvigo Prescription in Pennsylvania

Getting Dayvigo requires five discrete steps. The process is straightforward for most adults, though prior authorization can add 3 to 10 business days.

Step 1. Book a clinical visit. Choose a Pennsylvania-licensed provider. Telehealth platforms that hold Pennsylvania licensure can see patients statewide. In-person sleep medicine, psychiatry, or primary care offices are equally valid. Bring a medication list and your insurance card.

Step 2. Complete the insomnia evaluation. Expect questions about sleep latency (how long it takes to fall asleep), WASO, total sleep time, daytime impairment, and symptom duration. The International Classification of Sleep Disorders (ICSD-3) defines chronic insomnia as difficulty sleeping at least three nights per week for at least three months with associated daytime dysfunction [7]. If your symptoms meet that threshold, the provider has a defensible basis to prescribe.

Step 3. Confirm your pharmacy. Identify a Pennsylvania-licensed retail or mail-order pharmacy that stocks lemborexant. National chains (CVS, Walgreens, Rite Aid, Giant, Wegmans) and major mail-order pharmacies (Express Scripts, OptumRx, CVS Caremark) all carry Dayvigo. Licensed 503A compounding pharmacies in Pennsylvania may also dispense commercially available lemborexant, but compounding a Schedule V drug is heavily restricted; in practice, patients use commercial product.

Step 4. Handle prior authorization if required. Most commercial plans and Pennsylvania Medicaid require prior authorization (PA) before covering Dayvigo. The prescriber submits a PA form documenting the diagnosis code (F51.01 for primary insomnia or G47.00 for insomnia unspecified), symptom duration, and failure of at least one alternative agent. Common alternatives that insurers require a trial of first include zolpidem (Schedule IV) or cognitive behavioral therapy for insomnia (CBT-I). The Pennsylvania Department of Human Services Medicaid formulary covers Dayvigo at the preferred tier with PA [8].

Step 5. Fill and titrate. The FDA-approved starting dose is 5 mg taken no more than 30 minutes before bedtime, with at least 7 hours remaining before planned awakening [1]. The prescriber may increase to 10 mg if 5 mg is tolerated but insufficient. Dayvigo should not be taken with or immediately after a high-fat meal, which delays the time to maximum concentration (Tmax) by approximately 2 hours [1].

Telehealth Options for Dayvigo in Pennsylvania

Pennsylvania's telehealth prescribing environment is among the more permissive in the mid-Atlantic region. The Pennsylvania Medical Practice Act and the Pennsylvania State Board of Nursing both explicitly recognize synchronous audio-video encounters as valid for establishing a patient-provider relationship sufficient to support a prescription [4]. Asynchronous or "store-and-forward" consultations do not meet the standard for a controlled substance prescription; the visit must be live.

HealthRX connects Pennsylvania residents with licensed clinicians who evaluate and, where appropriate, prescribe lemborexant during a single synchronous video appointment. Patients in Philadelphia, Pittsburgh, Allentown, Erie, Harrisburg, and rural counties in central and northern Pennsylvania are all eligible, provided they have reliable internet or cellular service for the video call.

A 2022 analysis in the Journal of Clinical Sleep Medicine found that telehealth-delivered insomnia treatment reached patients at a median distance of 47 miles from the nearest sleep medicine specialist, underscoring the access gap that telehealth fills for rural Pennsylvania residents [9]. The same analysis reported that 78% of patients who completed a telehealth insomnia visit received a treatment recommendation within 24 hours.

After the visit, the provider sends the electronic prescription directly to the patient's chosen pharmacy. Standard retail pharmacy fulfillment in Pennsylvania typically takes same-day to 24 hours. Mail-order delivery of a 30- or 90-day supply generally arrives within 3 to 7 business days of prescription transmission.

Prior Authorization Requirements in Pennsylvania

Prior authorization is the most common barrier Pennsylvania patients face when filling Dayvigo. Understanding the documentation requirements before the appointment reduces delays.

Pennsylvania Medicaid (Medical Assistance) covers lemborexant under the Preferred Drug List with a PA requirement [8]. The criteria generally include: a diagnosis of chronic insomnia disorder, documentation that CBT-I was offered or attempted (or a clinical reason why it is contraindicated), and a trial or documented contraindication of at least one lower-cost alternative such as doxepin 3 mg to 6 mg or zolpidem 5 mg to 10 mg.

Commercial insurers operating in Pennsylvania, including Highmark, Independence Blue Cross, UPMC Health Plan, and Aetna, apply similar step-therapy requirements. A 2021 JAMA Internal Medicine analysis of insomnia drug prior authorizations found that step-therapy requirements delayed access to a prescribed medication by a mean of 8.3 days and led to treatment abandonment in 23% of cases [10].

Prescribers can accelerate approval by submitting the PA with the clinical note attached, including the ISI score, duration of insomnia, specific prior agents tried with dates and reasons for discontinuation, and the diagnostic code. An ISI score of 15 or higher indicates moderately severe insomnia and supports medical necessity [11]. Appeals are available if the initial PA is denied; Pennsylvania insurance regulations require insurers to respond to expedited appeals within 72 hours for urgent clinical situations.

Lemborexant Dosing, Safety, and Drug Interactions

The FDA label specifies two doses: 5 mg and 10 mg, taken once nightly [1]. The 10 mg dose should not be exceeded. Lemborexant is contraindicated with strong CYP3A inhibitors (ketoconazole, clarithromycin, ritonavir), which increase lemborexant plasma exposure by up to 4-fold [1]. Co-administration with moderate CYP3A inhibitors such as fluconazole requires dose reduction to 5 mg maximum. Strong or moderate CYP3A inducers (rifampin, carbamazepine, phenytoin) reduce lemborexant exposure and should prompt consideration of an alternative agent [1].

The FDA label also warns against use with other CNS depressants, including alcohol, benzodiazepines, and opioids, due to additive sedation risk [1]. Sleep paralysis, hypnagogic or hypnopompic hallucinations, and complex sleep behaviors (sleepwalking, sleep-driving) have been reported with orexin antagonists as a class. Patients should be counseled to report any complex sleep behavior immediately, and the drug should be discontinued if such behaviors occur.

Hepatic impairment matters. Patients with severe hepatic impairment (Child-Pugh C) should not use lemborexant [1]. Mild to moderate hepatic impairment (Child-Pugh A or B) requires a maximum dose of 5 mg. No dose adjustment is needed for renal impairment or in elderly patients, though the prescriber may choose to start at 5 mg in patients 65 years and older given pharmacodynamic sensitivity [1].

In SUNRISE-1, the rate of next-morning somnolence was 10% with the 10 mg dose versus 1% with placebo [2]. Patients who drive or operate machinery should be advised to assess their morning alertness carefully before doing so. The FDA added a class-level warning to orexin receptor antagonists in 2022 regarding next-morning impairment, reinforcing the 7-hour sleep-window recommendation [1].

What Labs Are Needed Before Starting Dayvigo in Pennsylvania

No specific lab panel is required before initiating lemborexant. This distinguishes it from some other sleep-related treatments where thyroid function, liver enzymes, or metabolic panels might precede prescribing.

Clinicians may order labs in specific situations. A comprehensive metabolic panel (CMP) is reasonable when hepatic impairment is suspected, because Child-Pugh staging changes the maximum permitted dose. A thyroid-stimulating hormone (TSH) level helps rule out hyperthyroidism as a reversible cause of sleep-onset insomnia. A CBC and iron studies are appropriate when restless legs syndrome complicates the insomnia picture, given that ferritin below 50 micrograms per liter is a recognized precipitant [12].

A formal polysomnogram is not required to prescribe lemborexant for clinical insomnia disorder. The AASM guideline notes that polysomnography is indicated when obstructive sleep apnea or periodic limb movement disorder is suspected, not for routine chronic insomnia evaluation [6]. If a prescriber suspects significant apnea (witnessed apneas, loud snoring, Epworth Sleepiness Scale score above 10), a home sleep apnea test or in-lab polysomnogram should precede DORA therapy, because sedating sleep agents may worsen apnea-related hypoxemia.

Transferring an Existing Dayvigo Prescription to Pennsylvania

Patients relocating to Pennsylvania who already have a lemborexant prescription from another state can transfer it to a Pennsylvania pharmacy with some caveats. Schedule V prescriptions may be transferred between pharmacies one time under federal DEA regulations, provided the receiving pharmacy is in the same state or a state that honors the original prescription [5]. If the prescription was originally written in a state whose DEA registrant number is not valid for Pennsylvania dispensing, the patient will need a new prescription from a Pennsylvania-licensed provider.

The practical path for most relocating patients: contact the new Pennsylvania pharmacy, provide the original prescriber's information, and ask the pharmacy to initiate the transfer. If the out-of-state prescriber is willing to send an electronic prescription directly to a Pennsylvania pharmacy, that is also valid and avoids the one-transfer limit. Patients who have ongoing telehealth relationships with a non-Pennsylvania prescriber should verify that their provider holds an active Pennsylvania license or compact license before continuing care.

Pennsylvania Pharmacy Options and Pricing

Lemborexant brand (Dayvigo) carries a retail cash price of approximately $420 to $480 for 30 tablets at major Pennsylvania chains as of mid-2025. GoodRx and similar discount programs do not typically produce large reductions for Schedule V branded drugs without manufacturer coupons. Eisai offers a co-pay assistance card for commercially insured patients that can reduce out-of-pocket cost to $30 per month for eligible patients; uninsured patients may qualify for the Eisai patient assistance program.

Pennsylvania's pharmacy network is dense. Philadelphia and Pittsburgh metros have multiple 24-hour pharmacies. Rural counties in northcentral Pennsylvania (Tioga, Potter, Clinton) have fewer retail options, making mail-order a practical choice. The Pennsylvania State Board of Pharmacy licenses mail-order facilities operating in the state, and national mail-order pharmacies holding Pennsylvania licenses may ship up to a 90-day supply of Schedule V medications [5].

For patients whose plan covers Dayvigo, the 30-day co-pay after prior authorization approval averages $15 to $45 on commercial plans, based on tier placement. Pennsylvania Medicaid co-pays for preferred drugs are capped at $3 per fill under current Medical Assistance rules [8].